NCT01402089View on ClinicalTrials.gov

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

November 30, 2015

Conditions
Non Small-cell Lung CancerRenal-cell CancerGastrointestinal Stroma Tumor
Interventions
DRUG

Sunitinib

Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)

DRUG

Erlotinib

Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.

DRUG

Midazolam

For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.

DRUG

Caffeine

For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.

Trial Locations (1)

9007

Cantonal Hospital St.Gallen, Sankt Gallen

All Listed Sponsors
collaborator

University of Basel

OTHER

lead

Markus Joerger

OTHER

NCT01402089 - Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | Biotech Hunter | Biotech Hunter